Recenty, in ‘AstraZeneca 21th Respiratory Week’, we saw Mr. ZHANG Yuren, a person in charge of parallel session. Through dialogue with Mr. ZHANG, we knows more about all procudures for pharmaceuticals and therapy commercialization.
It has been more than a decade since Mr. ZHANG Yuren diving deep in health industry. His endeavor has made him blossom in the field, as pharmaceuticals in particular. ZHANG has always entertained the feeling of pride being able to contribute to health science, especially after the outbreak of Covid-19. No other periods since the last half century can define the pivotal role of pharmaceuticals more than this couple of years where human beings are held hostage by the lethal virus.
His loyalty to pharmaceuticals stems from his abiding love to it and the sense of mission cultivated over the years. ZHANG started off as a doctor in 2011. During serving two hospitals as a physician and a gastroenterologist, he spent a big chunk of time investigating in pharmaceuticals and keen interests thus arose. He also found Chinese pharmaceuticals industry was yet to prosper and deserved more of explorations.
It saw his pivot in 2014 where he threw himself in pharmaceuticals by joining UCB (Zhuhai) Pharmaceutical Co., Ltd,, and being a regional medical consultant, committed in formulation of regional medical strategy for products, organization of education meetings both for doctors and patients, consensus on guidelines for cooperation etc. Benefited from the opportunities to communicate with medical professionals and participate different overseas academic conferences, ZHANG was convinced of the promising prospects of this industry, and was also building his pharmaceutical savvy that sets the stage for his career ahead.
In August 2016, ZHANG got on board in Bayer Healthcare Co. Ltd., a global enterprise dedicated in the life science fields of health care and agriculture, and he had kept thriving on his work as Medical Science Liaison. With an open and inquisitive mind, ZHANG was always able to come up with extraordinary solutions for every of his project, from organizing different medical events, to the analysis, research, popularization and application of the products used commercially or in clinical trials. No matter when he’s arranging the “INNOVATE” China Pilot International TL tour on AF management, or assisting the enrollment of patients in Xassure Research Regional Center, ZHANG received a great amount of accolades in recognition of his talents in pharmaceuticals and his professional skills as a medical science liaison. Solid track records were self evident, which got him further in being a pharmaceutical expert and brought him wide recognition in the field.
It was in August 2019 that ZHANG, with a stronger background in pharmaceuticals, was headhunted to AstraZeneca Investment (China) Co., Ltd. where he continued to contribute his wealth of experience. The position as senior medical advisor, an external and internal facing role, encompasses more vital work involving medical plan preparations, brand strategies, design and implementation of medical activities etc. His medical expertise, on par with his spirits in pushing the boundary forward, helped him go a long way in his work, with one of the noteworthy achievements in bringing in different pharmaceutical brands, Fluimucil and Broncho-Vaxom for example. There were a large quantity of tasks behind all this which calls for his highly professional skills, such as conducting medical research, medical guideline and consensus, medical education and support, but ZHANG always pulled them off and fully embodied what an outstanding brand owner can offer. Having managed to deliver high caliber of work and affirm what is best in a medical advisor, he got promoted last year to be Manager, Medical Compliance and had his sphere of duties extended far. He is now also looking after the review and approval of materials as well as activities of different projects, ensuring all of them working properly and smoothly. With a good head in pharmaceutical and a sharp eye to see through very target, he keeps bearing fruits in work and constantly demonstrate accomplishments like project management and approval for ‘Investigating the Clinical Features and Prognosis of Bronchiectasis Patients: a Multi-center, Primary Data, Cohort Study (ICON)’, organization for ‘AstraZeneca 21th Respiratory Week’, organization for webinars ‘Breathe Easy - Pragmatic Approaches to Addressing Respiratory Infections and Chronic Lung Disease in 2021’ etc., all of which have enhanced his armaments as a top-notch pharmaceutical expert. For good measure, ZHANG has thought big for his pharmaceutical career. He is going the extra mile and taking strategic initiatives to a wider range of projects, bringing more of his vision to life.
Since the pandemic, the medical systems have been suffering in many countries, and the development of healthy industry is on top of their lists. ZHANG also feels his solemn obligation to do more for pharmaceuticals and commercialization, to reclaim promises about defying the pandemic, and also for the long-term benefits echoing throughout human being’s life ahead.